Orion Corporation, Orion Pharma

• NCT06566989

  Collaborator, Phase 1, Completed, 8 people, 22 Aug 2024

• Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

  Collaborator, Phase 1/2, Recruiting, 220 people, 9 Apr 2024

• NCT06136598

  Collaborator, Phase 1, Completed, 14 people, 18 Nov 2023

• NCT06104449

  Collaborator, Phase 1, Completed, 7 people, 27 Oct 2023

• NCT04571996

  Phase 1, Completed, 4 people, 1 Oct 2020

• NCT03813277

  Phase 4, Completed, 60 people, 23 Jan 2019

• NCT03140956

  Phase 1, Completed, 20 people, 4 May 2017

• NCT03055936

  Phase 1, Completed, 56 people, 16 Feb 2017

• NCT02764125

  Phase 2, Completed, 84 people, 6 May 2016

• NCT02554734

  Phase 1, Completed, 15 people, 18 Sept 2015

• NCT02344017

  Phase 1/2, Completed, 23 people, 22 Jan 2015

• NCT02312232

  Phase 1, Completed, 20 people, 9 Dec 2014

• NCT02252523

  Collaborator, Phase 2, Status unknown, 66 people, 30 Sept 2014

• NCT01840423

  Phase 1, Completed, 101 people, 25 Apr 2013

• NCT01794975

  Collaborator, Phase 1, Completed, 8 people, 20 Feb 2013

• NCT01688089

  Phase 1, Completed, 67 people, 19 Sept 2012

• NCT01664520

  Collaborator, Phase 1/2, Completed, 10 people, 14 Aug 2012

• NCT01435213

  Collaborator, Phase 1, Completed, 10 people, 16 Sept 2011

• NCT01294163

  Collaborator, Phase 3, Completed, 509 people, 11 Feb 2011

• NCT01290146

  Collaborator, Phase 3, Terminated, 13 people, 4 Feb 2011

Sources: clinicaltrials.gov